



## Skeletal Effects of Soy Isoflavone in Humans: Bone Mineral Density and Bone Markers

Rehan Haider

University of Karachi

**Corresponding Author:** Rehan Haider [rehan\\_Haider64@yahoo.com](mailto:rehan_Haider64@yahoo.com)

---

### ARTICLE INFO

*Keywords:* Skeletal Effects, Soy Isoflavone, Humans, Bone Mineral Density

*Received :* 10 September

*Revised :* 16 October

*Accepted:* 11 November

©2023 Rehan. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International](https://creativecommons.org/licenses/by/4.0/).



### ABSTRACT

The potential skeletal effects of soy isoflavones in humans have garnered significant interest owing to their structural resemblance to endogenous estrogen and their potential to impact bone health. This abstract provides a concise overview of the current understanding of the effects of soy isoflavones on bone mineral density (BMD) and bone markers. Numerous studies have investigated the relationship between soy isoflavone consumption and BMD. Some studies have suggested a positive association between soy isoflavone intake and BMD, particularly among postmenopausal women. Isoflavones may exert their effects through estrogen receptor-mediated pathways, potentially mitigating bone loss by reducing osteoclastic activity and promoting osteoblastic functions. However, conflicting results have been reported, with certain studies demonstrating no significant impact on BMD. In addition to BMD, bone markers such as serum osteocalcin, urinary deoxypyridinoline, and tartrate-resistant acid phosphatase have been evaluated to elucidate the mechanistic effects of soy isoflavones on bone metabolism. These markers provide insights into bone turnover, resorption, and formation. Clinical trials have reported mixed findings regarding the influence of soy isoflavones on bone markers, reflecting the complexity of their interaction with bone physiology

## INTRODUCTION

This overview's goal is to draw attention to research on the effects of soy isoflavones, or isoflavones including soy protein, on human bone health. The significance of soybeans and their constituents in chronic illness prevention has been the subject of much research, with particular attention paid to cardiovascular health and resistance to the majority of malignancies. Therefore, more research on soy's role in bone fitness is warranted. The low incidence of hip fractures in Pacific Asians, the effectiveness of ipriflavone, an isoflavone derivative, in treating and preventing postmenopausal osteoporosis, the three, four, in vitro, five, and in vivo estrogenic pastimes of soy isoflavones, and the decreased urinary calcium losses in soy as opposed to diets high in animal protein are all indications that soybeans may also improve bone fitness. But still, These results refute the idea that soy isoflavones contribute to bone health. Thus, the evidence – while still preliminary – pointing to a possible protective impact of soy-containing isoflavones on bone is intriguing and motivating. This research focused on observational studies that used interventions. Studies on animal and in vitro mobility were not examined in the gift. The effects of soy isoflavones on bone mineral density (BMD), the use of dual-electricity X-ray absorptiometry (DXA), and biochemical markers of bone turnover evaluated in human blood or urine were the subjects of prospective study records that were submitted. A brief history of osteoporosis and the currently approved treatments is given before talking about soy isoflavones. Readers are referred to previously published analyses regarding the skeletal effects of soy isoflavones (8-14).

Several families of plant chemicals, including isoflavones, lignans, and coumestans, which share structural similarities with mammalian estrogens and have estrogenic activity in both human and animal tissues, are referred to as phytoestrogen.<sup>{15}</sup> Soy isoflavones, which share structural similarities with 17-estradiol, such as genistein, daidzein, and glycitein, are thought to offer protection against chronic illnesses such osteoporosis, breast cancer, and cardiovascular disease.<sup>{16}</sup> Clover and soybeans are used to extract phytoestrogens.

They can be purchased as supplements from the market. But as most research has been done on naturally occurring nonsteroidal isoflavones – which are mostly found in soy foods – this review concentrates on soy isoflavones. Men have not yet had research on BMD maintenance published; studies on women (pre-, peri-, and postmenopausal) have only been reported. The estrogen receptor (ER)-mediated pathway is hypothesized to protect bone mass in postmenopausal women due to a lack in endogenous estrogen, which is why dietary isoflavones are mildly estrogenic. Isoflavones bind to ERs, increase the development of the female mouse genital tract, cause estrus, and have an estrogenic effect on the central nervous system.<sup>"17"</sup> Because isoflavones bind to ER-18 preferentially, In comparison to traditional steroid estrogens, which bind to the ER preferentially, their activities are very different. While isoflavones may function as estrogen antagonists in reproductive tissues, they are modest 17B-estradiol agonists in bone cells. This suggests that varying concentrations of ER- and ER- in various cell types are the cause of the varied tissue response. Furthermore, since ER- has

been found in bone tissue, the greater affinity of isoflavones for ER-than for ER-may be especially significant. Shutt and Cox (20) found that in comparison to 17-estradiol, the relative binding affinities of genistein (0.9%) and dapzin (0.1%) are low. A significant amount of genistein's unique binding affinity for ER is lost when one of its hydroxyl groups – daidzein – is removed."21" Thus, given that certain tissues are primarily made of ER It is possible for isoflavones to have tissue-specific effects since different isoflavones behave differently. Isoflavones, therefore, act in a different way than medications referred to as selective estrogen receptor modulators (SERMs). Artificial studies have revealed that isoflavones together restrict and promote osteoblastic function; nevertheless, more research is required to identify which isoflavones inhibit and trigger cartilage friction in vivo.

**Phytoestrogens:** Phytoestrogens are plant-derivative compounds that structurally feature carnal estrogens and exhibit estrogenic action in animal and human tissues. They consist of isoflavones, lignans, and coumestans. Soy isoflavones, to a degree, genistein, daidzein, and glycitein, are structurally related to the birth control method 17-estradiol (a type of estrogen). These isoflavones are trusted to protect belongings against numerous never-ending illnesses, including osteoporosis, malignancy, and cardiovascular disorders.

**Form and supply:** phytoestrogens grant permission to be elicited from assets in the way that soybeans and prosperity While many types of phytoestrogen supplements are handy on stock exchanges, the review commonly trains in soy isoflavones because of the abundance of studies on nonsteroidal isoflavones from soy-located total pieces.

**BMD care:** The judgment climaxes that research has particularly intended young women (pre-, fairy-, and postmenopausal) for the guardianship of cartilage, not organic bulk (BMD) via digestive isoflavones. However, there is a lack of research on men in these circumstances.

**Estrogenic results:** Nutritional isoflavones exhibit feeble estrogenic results, particularly in the absence of inside estrogen, as noticed in postmenopausal schoolgirls. These belongings are expected to be interceded through estrogen receptors (ERs), which admit the memory of cartilage bulk.

**ER-binding particularity:** Isoflavones show an advantage for binding to the estrogen receptor being tested (ER-) over estrogen receptor alpha (ER-). This desire is solid because ER has been acknowledged in the cartilage fabric. The characteristic fabric reactions of isoflavones are due to the variable quantities of ER- and ER-indifferent container types.

**Selective Estrogen Receptor Modulators (SERMs):** Isoflavones reveal fabric-discriminating outcomes analogous to discriminating estrogen receptor modulators (SERMs), which are drugs that present images of estrogen agonists and antagonists in singular tissues.

**Osteoblastic appearance:** In vitro studies imply that isoflavones can both prevent and beautify osteoblastic traits. However, identical studies are wanted to decide in what way unique isoflavones affect in vivo cartilage friction.

## LITERATURE LITERATURE

### Epidemiologic Perspective Overview Of Osteoporosis

Osteoporosis is an epidemic that influences 25 heaps, giving the reason for 1.5 heapnew fractures each year in the US, and heaps of enormous heaps in general. Osteoporotic fractures cause big increases in healthcare costs and disabilities, accompanying rising public results in general. Men consistently cultivate fractures five years later than girls but contract an illness called osteoporosis nearly twice as frequently as wives. 22, Mothers who live longer tend to bear a heavier weight of sickness. Our group estimates that osteoporosis will cost \$60 billion by 2020.{25} Many fields of experience are seeing an increase in the occurrence of hip fractures, even though few have been secured.Earth.{26,27} The planned increase in the number of earlier men managed to increase the number of hips The number of fractures in general will increase from a supposed 1.7 heap in 1990 to a 6.3 heap in 2050, accompanying the adulthood of global chic fractures happening in Asia.{28} Currently, most fashionable fractures happen in Europe and North America, but an excessive

An increase This burden of disease will move from the industrialized world to the developing world due to an increase in the elderly population in South America, Africa, and Asia."29" Planning and distribution of effective stop designs are necessary in certain areas of the globe for fear of an anticipated increase in trendy fractures. Osteoporosis is defined as "an affliction from low cartilage bulk and microarchitecture decay of cartilage fabric superior to raised cartilage fragility and an aftereffects increase in fractures occurrence."{30} The World Health Organization (WHO) has grown into a functional

Definition of osteoporosis established BMD in young Caucasian wives Unfortunately, on account of the insufficient dossier on the connection middle from two points BMD and break risk in non-silvery sons or wives; The WHO does not Define osteoporosis for populations other than married Caucasian women."32" According to the WHO, osteoporosis is defined as a BMD for young mothers that is 2.5 standard deviations (SD) below the mean. According to the WHO, osteopenia is defined as a BMD for young spouses that is between 1 and 2.5 SD below the mean (also known as the correct score). A typical BMD is shown by a t-score that is between one standard deviation below the mean and some value above it. It is estimated that 54% of postmenopausal Caucasian wives in the US are osteopenic and 30% are osteoporotic based on these parameters. An increase in the SD below the mean (-1 t-score) doubles the risk of fracture for women. Nevertheless, drawbacks The rationale behind the use of a layoff is that changes in rupture risk are a clear and direct consequence of BMD. and there is no BMD in several risk variables.{34} Peak cartilage bulk, which is a crucial factor in predicting future rupture risk, is the highest BMD attained in the early stages of development. However, the age at which this happens changes indifferently, and changes accompany the wasted site The "Epidemiologic Attitude Evaluation of Osteoporosis" sector of the paper gives lively factual numbers on osteoporosis, allure incidents, effects, and demonstrative flags. Here is the breakdown of the key determinants referred to at this time.

**Osteoporosis incident and effect:** Osteoporosis is an implied epidemic that influences a large number of people. On my own in the US, it provides 1.05 heaps of new fractures done yearly, resulting in first-rate healthcare prices, disability, and public results. The far-reaching type of rupture is beginning to evolve significantly by way of factors such as growing longevity and changes in head count.

**Gender Disparities:** Osteoporosis influences both men and women; still, mothers are excessively distressed. Girls are more likely to extend fractures in advance compared to fathers, and the more interminable longevity of wives contributes to their lower disease burden.

**International occurrence:** While most hip fractures presently occur in Europe and North America, there can be a growing occurrence of hip fractures in several regions across the globe, especially in South America, Africa, and Asia. This shift was due to the growing older population in these regions.

Osteoporosis is defined as an ailment characterized by low bone mass and deterioration of bone tissue, mainly due to expanded bone fragility and a higher risk of fractures. The Sector Fitness Organization (WHO) has advanced the operational definition of osteoporosis based on bone mineral density (BMD) in younger Caucasian girls.

**BMD Thresholds:** The WHO defines osteoporosis as a BMD that is 2.5, famous deviations (SD), or greater than the suggested degree for more youthful girls. Osteopenia is defined as a BMD of 1 and a couple of five SDs below this notion. A t-rating within the range of -1 SD below the advised or better is considered via ordinary BMD.

**Fracture threat and BMD:** Fracture chance is simultaneously related to BMD, and for each well-known deviation (SD) under the mean (a -1 t-rating), a woman's risk of fracture doubles. However, the use of a cutoff for fracture threat has boundaries, as chance elements for fractures may be independent of the BMD.

**High Bone Mass:** High bone mass, the maximum bone density achieved in early maturity, is a crucial factor for predicting future fracture danger. However, the age at which individuals reach the highest bone mass varies among populations and skeletal sites.

This phase provides a complete overview of the prevalence, effects, diagnostic standards, and risk factors of osteoporosis. It sets the stage for discussing the capabilities and results of soy isoflavones on bone health in the following sections of this paper.

### **Bone Density and Fractures in Caucasian and Asian Populations**

Certain racial and ethnic groups may be more prone to osteoporotic fractures than others due to variations in bone morphology.<sup>{35}</sup> For instance, Mexican Americans and African American women, <sup>36</sup>, who have a lower fracture rate, are less at risk than Caucasian American women.<sup>{37}</sup> Taiwanese women experience a similar (18%) incidence of vertebral fractures as do Caucasian women, however the incidence of hip The incidence of fractures was lower among older Taiwanese people and those from mainland China.

Even with over 10 to 15% Taiwanese have a lower hip fracture rate than Caucasians, possibly as a result of structural differences between racial/ethnic groupings. They also have a lower femoral BMD. The hip axis length in premenopausal women was measured by the experts. Japanese Women of Indian descent in the subcontinent (41), as well as women residing in Australia (40), In contrast to their Caucasian peers, indicating structural variations. probably has a role in the differences in hip fracture prevalence between racial groups. 41 Researchers also looked into the factors that determine a woman's peak bone mass in China (43), the risk factors for hip fractures in Asian men and women (44), and the influence of lifestyle and anthropometric factors on peak bone mass in a multiethnic community {45}. There are some unexplained variations in osteoporosis risk among ethnic groups, however there may be mostly attributable to variations in picture size, which cause size-related errors in BMD measurements (46, 47) and variations in hip axis length (48, 49) when BMD is compared between ethnic groups. For effective interpretation of spine BMD data, image sizing must be adjusted. Similarly, hip geometry must be taken into account for an accurate assessment of hip fracture risk.48 Variations in the risk of osteoporosis may also be associated with culturally particular characteristics that be mostly attributable to variations in picture size, which cause size-related errors in BMD measurements (46, 47) and variations in hip axis length (48, 49) when BMD is compared between ethnic groups. For effective interpretation of spine BMD data, image sizing must be adjusted. Similarly, hip geometry must be taken into account for an accurate assessment of hip fracture risk.48 Variations in the risk of osteoporosis may also be associated with culturally particular characteristics that to diet and exercise, which are beyond the scope of this review.

The "Caucasian vs. Asian Populations: Bone Density and Fractures" section of the paper discusses the ethnic and genetic differences in bone density and fracture susceptibility between different population groups. A breakdown of the key points mentioned in this section is as follows:

**Ethnic and Genetic Differences:** Different ethnic and genetic backgrounds can lead to variations in the susceptibility to osteoporotic fractures. For instance, Caucasian American women are at a higher risk of fractures than African-American and Mexican-American women. These variations are likely to be influenced by genetic and structural differences.**Incidence of Fractures:** Incidence rates of fractures can vary between different racial and ethnic groups. The incidence of vertebral fractures among Taiwanese women is comparable to that of Caucasian women; however, the incidence of hip fractures is lower among older Taiwanese individuals and those from mainland China. These differences in fracture rates suggest that factors other than bone density may also play a role.**Structural Differences:** Even though Taiwanese individuals have 10–15% lower femoral bone mineral density (BMD) than Caucasians, they exhibit a lower rate of hip fractures. This discrepancy could be attributed to structural differences in hip geometry between racial and ethnic groups.

**Hip Axis Length:** Studies comparing hip axis length in different racial groups have indicated that structural differences likely contribute to variations

in the prevalence of hip fractures. Differences in hip geometry can affect the distribution of forces on the hip joint and fracture risk.

**Determinants of Bone Mass:** Research has focused on investigating the factors that contribute to peak bone mass and fracture risk among various ethnic groups. These factors include anthropometric measurements, lifestyle factors, and risk determinants in both men and women.

**Image Size and BMD Measurements:** When comparing bone mineral density (BMD) across different ethnic groups, it is crucial to correct the image size to ensure an accurate interpretation of spine BMD values. Additionally, considering hip geometry is essential for accurately assessing hip fracture risk.

**Cultural Factors:** Differences in osteoporosis risk between ethnic groups might also be related to culturally specific factors such as diet and exercise. However, these cultural factors were not discussed in detail in this review.

This section highlights the importance of considering ethnic and genetic variations when assessing bone density and fracture risks. This suggests that factors beyond bone mineral density, including structural differences and cultural factors, contribute to the differences in fracture rates observed among different racial and ethnic groups.

### **Oy Intake, Bone Density, and Fractures**

The low incidence of hip fractures in Asians has been attributed to the beneficial effect of isoflavone-containing soybeans on bone health. However, human studies have found that isoflavone-rich soy protein intake (40 g/day) was associated with beneficial effects on the spine (51, 52) but not on the femoral (hip) bone. Also, the number of isoflavones (in aglycone form) consumed by subjects in high isoflavone groups in these two studies (80 or 90 mg/day) were higher than what is typically consumed by 54 women or women from Hawaii's multiethnic community, either Chinese (39 mg/day) or Japanese (23 mg/day) (range from 5 mg/day in Filipino to 38.2 mg/day in Chinese). However, it's feasible that less. Over time, consuming large amounts of soy isoflavones may have a major beneficial influence on bone health. However, variations in the frequency of spine fractures are not. Apparent 56, 57, or lumbar spine MD 47, 558} in Asians compared to Caucasians. In contrast, higher spine and hip BMD values were reported in US-born Japanese. Women vs. men in Japan Asians may have reduced hip fracture rates for a variety of reasons, however Asians of Pacific descent may be more susceptible due to their shorter hip axis lengths.48,49 Unknown. Asians are less likely to fall between the ages of 60 and shorter, which is a protective factor. Height of Asians 43 Despite the lack of practical benefit, these uncontrollable factors can reduce the chance of fracture, MD, or hip fractures. In a study of 478 postmenopausal Japanese women, Somekawa and colleagues 61 investigated the connection between soy isoflavone consumption, menopausal symptoms, lipid profiles, and spinal BMD as determined by DXA. They found that BMD values varied considerably among the four levels of isoflavone intake, ranging from 35 mg/day to 65 mg/day in the early ( $p < 0.001$ ) and late ( $p \leq 0.01$ ) postmenopausal groups, after controlling for BMD for weight

and years after menopause. correspondingly. The BMD was higher in women who consumed more soy isoflavones.

Regarding the other factors (i.e., years, weight, and height), the variations were not significant. for isoflavone consumption, cholesterol, or lipoprotein concentrations) during menopause.

Additional research (N = 995) in middle-aged Japanese women (40–49 years) looked at the connection between soy consumption and other dietary variables and metacarpal BMD as determined by computerized X-ray densitometry.<sup>62</sup> When age, height, weight, and weekly calcium consumption were taken into account, the tendency (p = 0.03) for women to have higher BMD when consuming soybeans at least twice a week remained true. Along with a basic analysis of data from the Study of Women's Health Across the Nation (SWAN), Japanese premenopausal women with the highest vs. 7.7% tertile of genistein intake and 12% greater spine and femoral neck BMD were found in a US community-based cohort study of women aged 42 to 52 years. Not one of The moderate intake (g/d) of genistein in Chinese women was found to be associated with BMD, presumably because it was lower than that of Japanese women (7151 g/d). Kardinaal et al. (64) investigated the hypothesis that the urinary excretion of phytoestrogens, a biomarker of long-term dietary intake, is inversely associated to the rate of postmenopausal radial bone loss as assessed by single-photon absorptiometry in the Netherlands. They found, against their hypothesis, that urine enterolactone excretion was higher in women with relatively high rates (1.91 ± 0.08%) of annual bone loss (median = 838 vs. 1108 g/g) than in women with relatively low rates (0.27 ± 0.08%) of loss. Enterolactone is produced by colonic bacteria using precursors present in grains, legumes, seeds, and vegetables.<sup>65</sup> Nevertheless, the levels of genistein, daidzein, and The equol in the two groups was the same. Moreover, the intake of dietary isoflavones by this group of women was relatively low, comparable to what Dutch women generally ingest. On the other hand, 66 prospective research on the relationship between soy food intake and fracture risk in almost 75,000 Chinese postmenopausal women revealed that soy protein intake had a preventive effect. Once age, BMI, energy and calcium intake (along with other dietary factors), lifestyle risk factors like osteoporosis, and socioeconomic status were taken into account, the relative risk of fracture varied between the highest and lowest quintile of soy protein intake (p < 0.001), with an even stronger inverse association observed among women who had just gone through menopause. There are differences in the nature and size of these published investigations. of bones in addition to the quantity of dietary isoflavones that are normally consumed. The effect of soy-derived isoflavones on bone, however, appears to be more pronounced in the perimenopausal period than in the late postmenopausal years, and the evidence appears to be stronger for trabecular (i.e., vertebral) bones than cortical (i.e., radial, metacarpal) bones. This is likely dependent on usual intake.

The "Soy Intake, Bone Density, and Fractures" section delves into the relationship between soy intake, bone density, and fractures, specifically focusing on the effects of isoflavone-containing soybeans on bone health. Here's a breakdown of the key points mentioned in this section:



**Hip Fracture Incidence in Asians:** The low incidence of hip fractures in Asian populations has been attributed to the potentially beneficial effects of soy isoflavones on bone health. However, studies have produced mixed results regarding the effects of isoflavone-rich soy protein intake on bone density, particularly in the hip region.

**Isoflavone Intake and Bone Health:** Human studies have shown that higher isoflavone intake from soy protein may have beneficial effects on spinal bone mineral density (BMD) but not on femoral (hip) bone density. Notably, the levels of isoflavones consumed in certain studies exceeded the typical dietary consumption in Asian populations.

**Ethnic and Geographical Differences:** Ethnic and geographical differences may contribute to variations in hip fracture rates and bone density. For example, US-born Japanese women have been found to exhibit higher spine and hip BMD values than Japanese women. Structural differences, tendencies to fall, and stature variations have been cited as potential contributors.

**Relationship between isoflavones and bone density:** Previous studies have investigated the correlation between soy isoflavone intake and bone density. One study in postmenopausal Japanese women found significant differences in BMD values based on isoflavone intake levels, indicating a potential positive relationship between higher isoflavone intake and BMD.

**Dietary Factors and Bone Density:** Research has explored the impact of dietary factors, including soy intake, on bone density. Japanese women who consumed soybeans at least twice a week showed a higher bone density than those with lower soy consumption. A US-based study also revealed an inverse association between genistein intake and BMD in premenopausal Japanese women.

**A Prospective Study in Chinese Women:** A prospective study involving postmenopausal Chinese women indicated a protective effect of soy protein intake on fracture risk. This study found a significant inverse association between soy protein intake and fracture risk after accounting for various factors.

**Evidence for Isoflavones and Bone Health:** The Evidence for the impact of soy-derived isoflavones on bone health appears to be stronger for trabecular (vertebral) bone than for cortical (radial, metacarpal) bone. The effects may also vary based on the perimenopausal period rather than the late postmenopausal period.

This section presents a range of findings related to the effects of soy isoflavones on bone density and fracture risk. The results are varied, and factors such as bone type, usual isoflavone intake, and menopausal stage seem to influence the outcomes observed in different studies.

### **Current and Potential Alternative Treatments for Osteoporosis Estrogen Therapy/Hormone Therapy**

Increased cartilage misfortune at some stage of perimenopausal age has been attributed to estrogen deficiency as a result of ovarian decline. This cartilage deficit contributes to a 20–30% deficit in cancellous fabric (trabecular) cartilage and a 5–10% lack of cortical cartilage (67) and provides permission to resume for many years after the cessation of the menstrual cycle. Estrogen precise (estrogen

evaluation) or together with progestin (hormonal treatment) averts cartilage loss within the spine and stylish 68 and decreases the occurrence of hip fractures. Domestically alive tumor determinants and cytokines harmonize the consequences of estrogen on osteoblasts and osteoclasts, leading to a cartilage deficit. Estrogen deficiency plays a key role in osteoporosis and further incessant illnesses such as manual midlife melancholy; however, the start-manipulation method remedy is often followed via aftereffects and will increase the risks of endometrial malignancy, invasive bosom tumors, and common cardiovascular (arterial and venous) disease. {73} Estrogen or birth control technique treatments relieve vasomotor signs and symptoms, forbid cartilage misfortune, and decrease the threat of colorectal tumors and hip fractures. However, disobedience is the primary obstacle to common hormone remedies detrimental effects and the fear of malignancy.2-3 of something of a daughter's droop remedy due to antagonistic aftereffects inside the five years of advent The seventy-seven} remedy decided at the onset of the cessation of the menstrual cycle, resumed at inferior 10 years of age but discontinued from that time forward, has little, if any, impact on spoil prevalence at age 70. 69; therefore, when the situation is ended, cartilage loss trails, corresponding to what happens following menopause.{78} Clinical Instructions no longer approve the beginning manipulation method as a first-line remedy for the treatment of postmenopausal osteoporosis. These days, studies have concentrated on alternatives to steroid hormones, with their corresponding waste and cardiovascular advantages but with out-of-doors side effects. An overview of these options for steroid hormones for the prevention and remedy of osteoporosis is bestowed within the following four subsections:

The "cutting-edge and capacity opportunity treatments for Osteoporosis: Estrogen remedy or hormone remedy" section discusses the role of estrogen therapy or hormone remedy in stopping bone loss during menopause. Here's a breakdown of the key points stated in this segment:

**Estrogen Deficiency and Bone Loss:** The perimenopausal length is related to expanded bone loss because of estrogen deficiency as a consequence of ovarian failure. This results in substantial loss of both cancellous (trabecular) and cortical bone.

**Estrogen remedy and Bone health:** Estrogen therapy, either alone or mixed with progestin (a hormone remedy), has been shown to save you from bone loss in the backbone and hip, thereby decreasing the chance of hip fractures. Estrogen influences osteoblasts and osteoclasts via locally lively boom elements and cytokines.

**Blessings and risks of Hormone therapy:** Estrogen deficiency is a key factor in osteoporosis and different menopause-related persistent sicknesses. Estrogen or hormone therapy gives blessings, including assuaging vasomotor signs, preventing bone loss, reducing the chance of colorectal cancer, and decreasing the hazard of hip fractures. However, hormone remedies are associated with side effects and multiplied risks of endometrial cancer, invasive breast cancer, and cardiovascular illnesses.

**Demanding situations with Hormone remedies:** no matter the advantages, non-compliance with hormone therapy is common because of detrimental

outcomes and concerns approximately most cancer risks. Many girls stop taking medication within 5 years due to these troubles. Starting treatment at the onset of menopause but discontinuing it after much less than 10 years yields constrained consequences for fracture prevalence at later ages.

Pointers and options: Scientific guidelines do not endorse hormone therapy because it is the first-line remedy for postmenopausal osteoporosis prevention. As an opportunity, research has centered on locating remedies with skeletal and cardiovascular advantages comparable to steroid hormones but without the related adverse outcomes.

This phase highlights the advantages of estrogen remedies or hormone therapy for preventing bone loss throughout menopause. However, it also underscores the demanding situations associated with those remedies, leading to the exploration of alternative options for osteoporosis prevention and treatment.

### **Bisphosphonates**

The most potent class of bone-active drugs are derivatives of pyrophosphate and bisphosphonates, which are potent inhibitors of bone resorption. They are safe and effective in treating and preventing osteoporosis, including that brought on by corticosteroids, and have a great affinity for bone, boosting bone mineral density (BMD). Prospective trials have demonstrated the ability of alendronate (Fosamax®), risedronate (Actonel®), and etidronate (Didrocal®) to lower the risk of vertebral fractures. It has been demonstrated that alendronate and risedronate are more effective than etidronate in preventing hip fractures. The FDA has approved alendronate and risedronate for the treatment of postmenopausal osteoporosis, the prevention of early postmenopausal bone loss in women, and the management of glucocorticoid-induced bone loss. When combined with estrogen, bisphosphonates enhance bone mineral density (BMD) more than when used alone definite if there will be a decrease in the risk of fractures.

### **Calcitonin**

Calcitonin is an antiresorptive agent approved by the FDA for the treatment but not the prevention of <85} Osteoporosis The benefits of calcitonin include its specificity for bones, its analgesic properties, its potential as an estrogen substitute, and its applicability to men. Biochemical bone marker turnover has demonstrated that a single dose of nasal calcitonin reduces bone resorption by 15%, while its anabolic effect is unknown and it does not seem to have long-term efficacy. While calcitonin lowers the risk of vertebral fractures by up to 40%, it has no effect on nonvertebral fractures or BMD, such as those of the hip.

### **Calcium and Vitamin D**

Since all nutrients are necessary for the cellular function of bone cells, diet has a significant impact on the onset, management, and prevention of osteoporosis. An in-depth examination is outside the purview of this chapter; the reader is referred to an outstanding review of dietary components that impact bone 88. Although they are not sufficient treatments on their own, calcium and vitamin D are useful complimentary therapies for the diagnosis, management, and prevention of osteoporosis. Still, they play a big part when combined with antiresorptive drugs like calcitonin, estrogen, bisphosphonates, or SERMs.

Sufficient calcium intake and adequate vitamin D status prevent bone loss and lower the incidence of fractures, particularly as one ages and in the peri- and post-menopausal years (89).<sup>90</sup> Them Because of changes in age-related absorption and excretion as well as bone growth, the need for calcium and vitamin D varies throughout life. For calcium, the recommended dietary reference intake varies from 210 mg/era at the beginning to 1300 mg/era; for vitamin D, it ranges from 5 g/day (200 IU) from birth over 50 years to 15 g/day (600 IU) after age 70 during adulthood. The consent belief of the North American Menopause Society<sup>89</sup> plans that most women need not completely 1200 mg calcium per epoch, accompanying 400 to 600 IU (10 to 15 g) of source of nourishment D per day from cuisine beginnings or supplements, apart from sunlight exposure to guarantee enough amounts of calcium incorporation. The colossal majority (50 of 52) of calcium interference troubles and 75% of 86 practical studies (92%) have proved that high calcium consumption advances cartilage energy. Estrogen therapy shows a considerably better securing effect when executed simultaneously with additional calcium than when captured individually. Substances that increase bone mass (that is, fluoride and bisphosphonates)

However, they do not reach their complete effect when calcium is restricted. Vitamin D facilitates osteoclastic friction and sane mineralization, in addition to the incorporation of calcium and phosphorus. Vitamin D supplementation is exceptionally important for the elderly; it is often imperfect and helps defeat raised levels of the antitoxin parathyroid birth control method (94, 95), which leads to cartilage misfortune. Vitamin D supplementation is guiding a meaningful annual increase in BMD at the lumbar spine ( $p \leq \text{nothing.0001}$ ) and femoral narrow connector ( $p = \text{nothing.03}$ ) in sufferers accompanying osteopenia.<sup>{96}</sup> Calcium and vitamin D supplementation on my own is incompetent, but it's a pillar in the prevention and remedy of osteoporosis. The "Bisphosphonates," "Calcitonin," and "Calcium and Nutrition D" divisions provide a top-grade view of different remedy substitutes for osteoporosis. Here's a disintegration of the important determinants noticed in these portions:

### **Bisphosphonates**

Bisphosphonates are effective inhibitors of bone friction and have the best-choice cartilage-active powers for treating osteoporosis.

They have a strong similarity for bone, superior to raised cartilage, not organic density (BMD), and lower the hazard of fractures that comprise vertebral and stylish fractures.

Alendronate, risedronate, and etidronate are substances that have proven influential in depreciating the hazards of vertebral fractures. Alendronate and risedronate are FDA-certified for numerous signs associated with osteoporosis, to a degree postmenopausal cartilage misfortune, and glucocorticoid-prompted cartilage misfortune.

### **Calcitonin**

Calcitonin is an antiresorptive power continually secondhand for treating osteoporosis, in spite of the fact that it is no longer secondhand for stopping. It has bone-particular shifts and a painkiller impact, making it a hope for estrogen. It may be more employed by brothers.

Calcitonin ability does not have long-term efficiency in conditions of cartilage absorption but has shown a discount in cartilage friction. At the same time, as it does not affect nonvertebral BMD or fractures, it can reduce the danger of vertebral fractures by nearly 40%.

Calcium and diet D:

Nutrients play a considerable role in cartilage bettering, stopping, and situation of osteoporosis Calcium and vitamin D are strong complementary remedies, in addition to antiresorptive agents. OK, diet D acknowledgment and enough calcium use are fault-finding for staying bone deficit and fractures, especially during the whole of midlife depression and with age. The urge pertaining to food remark consumption for nutrition D levels ranges from 5 g/era (100 IU) initially to 15 g/epoch (600 IU) subsequently age 70. Calcium requirements range from 210 mg/epoch at first to 1300 mg/era sometime in childhood. Consensus desires that most schoolgirls want not completely 1200 mg of calcium per epoch and 400 to 600 IU (10 to 15 g) of weight deficit program D per epoch through food or pertaining to food dietary supplements.

Calcium and food Vitamin D supplementation is a mainstay in the stop and remedy of osteoporosis, helping in growing BMD and lowering cartilage misfortune.

These portions provide a complete appraisal of those situational options and their parts in coping with osteoporosis and emphasize their influence, clues, and benefits for cartilage health.

### **Selective Estrogen Receptor Modulators(SEEMS)**

Selective estrogen receptor modulators are composed of a group of chemically various nonsteroidal entities that bind to and communicate with the estrogen receptor. These estrogen-like compounds exhibit fabric discrimination, indicating that a likely SERM may be a part of an estrogen agonist in a few tissues and an estrogen enemy in the remainder of something. {97} Structurally and pharmacologically similar to soy isoflavones, artificial SERMs (to a degree, ipriflavone, tamoxifen, and raloxifene) are active in blocking or lowering bone misfortune. An isoflavone derivative of plant inception (98), ipriflavone, was secondhand for the stop and treatment of postmenopausal osteoporosis (3, 4, 99), in addition to various models of exploratory osteoporosis.{100,101} Ipriflavone again enhances the healing cartilage reaction when linked with estrogen, which is above the accompanying distinct therapy.{102} In contrast, a multicenter study<sup>103</sup> disclosed that ipriflavone hinders cartilage deficit or affects cartilage change, which raises doubt about its influence. Tamoxifen is widespread; it is secondhand in the situation of breast tumors but further has feeble estrogenic effects on bone renovation.{104} A randomized dispassionate trial accompanied that while the fake pill group lost 1% following in position or time individual period, the tamoxifen-105 group had a considerably increased backbone BMD (0.6%). These advantageous wasted belongings of tamoxifen have been rooted in added studies, but allure's main disadvantage is endometrial provocation (106); unlike tamoxifen, raloxifene does not provoke the endometrium (107), but it protects against cartilage misfortune and repair (108); therefore, the FDA has certified raloxifene for the stop of postmenopausal osteoporosis. A loss of

raloxifene is that it concedes the possibility of increasing hot flashes in a few mothers (109), accordingly possibly limiting allure use to those who are well past midlife depression. Even more current research has shown that, compared to a fake pill, raloxifene does not increase the commonness or severity of new flashes in girls. {110} Interestingly, a 24-temporal length of event or entity's existence study found that isoflavone-rich soy had no unfavorable or beneficial effects on vasomotor function manifestations in perimenopausal girls. The mechanism of operation of SERMs on cartilage is complementary to estrogen in lowering bone friction. These potential advantageous belongings of SERMs have excellent appeal in the prevention and situation of osteoporosis; still, simply happening soy isoflavonoids may be more agreeable to many menopausal mothers than artificial analogs.

### **Oy Isoflavones: Potential Alternative for Osteoporosis Prevention**

Because they protect the bones, isoflavones may have the most promising effect on women going through menopause. It has been shown that isoflavone-containing soy protein isolates can momentarily halt the loss of lumbar and femoral bone in ovariectomized rats as well as the loss of bone in the human lumbar spine. Number Five Just one Clinical trials involving humans will eventually be required to confirm the long-term effects of soy isoflavones, despite the fact that research on animals can provide valuable insights into potential mechanisms of action. Numerous clinical trials conducted worldwide have examined the impact of soy meals, isolated soy protein, or isolated isoflavones on the bone mineral content (BMC), BMD, and bone biochemical markers of middle-aged women. First, we examined the impact of isoflavone-containing soy protein on calcium metabolism, which is an additional potential mechanism that It is thought that soy isoflavones contain the bone.

Two parts that highlight significant research on the impact of soy isoflavone consumption on human protein and calcium homeostasis, as well as BMD and biochemical markers of bone, will follow the first section. Soy proteins may offer some indirect protection against bone loss through mechanisms unrelated to their estrogenic effects. Similar to how estrogen improves calcium uptake in vitro, isoflavones can also increase the absorption of calcium. However, a recent human study found that neither enriched nor depleted soy protein isoflavones appeared to affect net calcium retention or fractional calcium absorption."114 Kinetic modeling revealed that bone deposition was 20% higher in the soy diet containing isoflavones than in the soy diet excluding isoflavones (N=14) However, there was no statistically significant change. Nevertheless, when compared to the casein-whey protein control diet, soy intake decreased urine calcium excretion ( $p < 0.01$ ), regardless of isoflavone content. Therefore, compared to diets strong in animal proteins, soy-rich diets can reduce the amount of calcium lost through the urine. Compared to beef, the amount of sulfur amino acids in beans and other legumes is slightly lower. Animal protein has been shown to be more hypercalciuric than soy-based protein in human studies (7, 116, 117), most likely as a result of increased net renal acid excretion associated with a high-meat diet.118 in Over the course of a day, direct comparisons were done between the methionine concentrations of whey (2.8 g/100 g) and soy

protein (1.3 g/100 g).16%. After four hours, consuming whey increased the urine's calcium: creatinine ratio by 45 percent. but only by 3% when a comparable amount of soy was consumed. main source of protein. After 24 hours, the whey group's calcium: creatinine ratio was 56% greater than the soy group's, which was 27% higher. Participants (N = 9) with ages ranging from 22 to 69 years were fed protein (~ 80 g) primarily from chicken or soybeans, as well as similar amounts of calcium, phosphorus, magnesium, and sulfur, during a two-week study. The total titratable acid in urine increased by 46% with meat diets, but only by 4% with soy diets as compared to baseline values. Compared to meat protein, soy protein was less hypercalciuric, as seen by the 169 mg of calcium excreted in urine from the soy diet and the 203 mg in the diet of meat. Similar to this, Breslau et al.<sup>7</sup> investigated calcium metabolism in 15 individuals, ranging in age from 23 to 46, who took Participants were randomly assigned to one of three diets for a duration of 12 days: animal proteins (beef, chicken, fish, or cheese), soy protein (vegetarian), or soy plus egg proteins (ovo-vegetarian). Protein (75 g/day), phosphorus (1000 mg), calcium (400 mg), salt (400 mg), and water (3 L) were all energy-dense and stable. The researchers observed that while there was no variation in fraction 47 of dietary calcium absorption, 24-hour urine calcium excretion increased ( $p < 0.02$ ) from  $103 \pm 15$  mg/day to  $150 \pm 13$  mg/day when an animal protein diet was followed. In a similar vein, Pie and Paik<sup>117</sup> offered young Korean women for five days. a diet consisting of soy (83 g protein/day) and pork (71 g protein/day) for (N = 6). Urine showed a similar daily consumption of calcium (525 mg) from the diet. The participants' fecal calcium excretion was higher ( $p < 0.025$ ) when they ingested meat (127 and 467 mg/day) compared to a soy-based diet (88 and 284 mg/day). Consequently, beef had a worse overall calcium balance in the diet (-65.4 mg/d) than soy (155.3 mg/d) ( $p < 0.001$ ). When 25 g of soy protein was given daily to healthy postmenopausal women in place of their regular meat protein in a varied diet, neither calcium retention nor bone markers improved or declined over the course of seven weeks. In this crossover study with randomized controlled feeding, there was no difference in the amount of calcium excreted in the urine between the soy Despite higher urine pH and lower renal acid excretion (ammonium plus titratable acidity) in the protein group and the control group. One possible explanation for the inconsistent findings of these studies is that increased intestinal calcium absorption—which is dependent on several factors—causes protein-associated hypercalciuria instead of increasing bone resorption."<sup>121</sup> An analogous question is whether Asians, who typically consume 500 mg/d of calcium and have smaller frames than Caucasians (1200 mg/day; age 50+), ought to adhere to the same recommendations."<sup>122</sup> In non-osteoporotic postmenopausal Chinese women, Kung et al. (123) found that after a calcium deficit ( $< 300$  mg/d), absorption of calcium increased to 71%, from 58% with a 600 mg supplement to 60% during an unchanged time. These absorption values are twice as high as those of Caucasians."<sup>124</sup> Considering the Chinese, who eat 41% of the soy and vegetables in the world, absorb calcium differently? of their calcium in contrast to the 10% consumed in the US?Further research is needed to determine the precise long-term effects of soy on calcium and bone homeostasis. Therefore, the

benefits of soy-based diets for calcium excretion may have practical applications in medicine. Individuals who consume two or three portions daily and replace soy with animal protein have the potential to gradually shift the balance in favor of calcium retention.

### **Prospective Research on Soy Isoflavones on Bone Mineral Density**

Two of the most noteworthy prospective studies looked at the typical consumption of soy foods among participants, and six employed soy protein isolate 51, 52, 127, 128 or soy protein food 129, 130 as a source of isoflavones. Asians 66, 131 as a source of isoflavones; three others employed isoflavones that were derived from soy.// 132-134} A summary of one of these studies, which looked at the relationship between soy consumption and fracture risk, may be found previously in Section 2C. It was the express purpose of two interventional studies (51 and 130) to look at primary bone outcomes. The following summary of nine studies (51, 52, 127-133) shows the range of current knowledge on soy isoflavones and bone. Using a crossover design, Dallas and colleagues 129 gave 44 postmenopausal women 45 g of soybean meal (flour) with 53 mg/d of isoflavones, 45 g of linseed (linseed with precursors of mammalian lignans), or 45 g of wheat granules (control) every day for 12 weeks. They discovered a rise in total body BMC. BMD remained unchanged but increased by 5.2% ( $p = 0.03$ ) in soybean, 5.2% (NS) in linseed, and 3.8% (NS) in wheat. There was an increase in BMC in the other two groups, one of which was the control group, however the amount of this increase was improbable. As such, care should be taken while interpreting these results. 52 In an additional study aimed at examining the effects of soy protein on lipids, 66 postmenopausal women with high blood pressure were randomly assigned to receive one of three treatments for a period of six months: (1) casein + protein from skimmed milk powder, (2) soy protein isolate (40 g/d) with 56 mg/day isoflavones, or (3) SPI+ with 90 mg/day isoflavones. The ladies varied in age (ranging from 49 to 83 years) and the length of time they had been menopausal. In the isoflavone group, women underwent a modest decline in lumbar spine BMD and BMC was observed in the casein and milk group, whereas there was an increase (2%;  $p < 0.05$ ). Despite beginning the trial with lower BMD and BMC than the other two groups, the women in the isoflavone group did not take these baseline values into account. Baseline BMD should be taken into consideration since individuals with lower bone mass typically experience larger effects from treatment (135).

Nonetheless, the Alekela et al.<sup>51</sup> study, which involved 69 perimenopausal women, generally concurs with the earlier research that was discussed. Women were randomized (double-blind) to receive whey protein (control;  $n = 21$ ), low isoflavone soy (SPI, 4.4 mg/day;  $n = 24$ ), or isoflavone-rich soy (SPI+, 80.4 mg/d;  $n = 24$ ) as their treatment. Not a shift was recorded in SPI+ (-0.2%,  $p = 0.7$ ; +0.6%,  $p = 0.5$ ) or SPI (0.7%,  $p = 0.1$ ; 0.6%,  $p = 0.3$ ), whereas reduction ( $p = 0.004$ ) in lumbar spine BMD and BMC happened in controls (-1.3%, -1.7%). Regression analyses and an analysis of covariance (ANCOVA) took baseline values into account as they had a negative impact ( $p < 0.0001$ ) on the percent change in these outcomes. The change in BMD ( $p = 0.25$ ) was not significantly affected by therapy, according to ANCOVA data, however the



change in BMC ( $p = 0.021$ ) was. Furthermore, isoflavones – not soy protein – had a beneficial effect, according to contrast coding using an ANCOVA with BMD or BMC as the result. Taking into account a number of relevant elements, such as weight gain, Analysis of regression revealed that SPI+ had a favorably impacted the percentage changes in BMDs (5.6%,  $p = 0.023$ ) and BMC (10.1%,  $p = 0.0032$ ). The percent decrease in BMD was correlated with initial body weight rather than final weight or weight gain, indicating that weight gain had no effect on SPI+'s bone-damaging effects. The authors' hypothesis was not supported by their findings, which showed no endogenous influence of reproductive hormones or estrogen status on bone loss. Whey protein and soy (SPI) had no effect on the spine, and therapy generally had no effect on any other bone sites. The idea that isoflavones are a bioactive component of soy with regard to bone health is supported by these final two investigations.

Another study was designed to investigate habitual soy intake and BMD in premenopausal Chinese women aged 30–40 years living in Hong Kong.<sup>131</sup> After adjusting for age and body size (height, weight, and bone area), researchers noted a positive effect of soy isoflavones on spinal BMD after a mean follow-up of 38.1 months. The average percentage decrease in BMD of the spine in a total of 116 females was greater ( $p < 0.05$ ) in the lowest (-3.5%) vs. the highest (-1.1%) quartile of soy intake of isoflavones. Multiple regression analysis revealed that soy isoflavone intake (along with lean body weight, physical activity, energy-adjusted calcium intake, and follow-up duration) accounted for 24% of the variation in spine BMD in these women. This 3-year study showed that soy isoflavone intake had a positive effect on the maintenance of spine BMD in 30- to 40-year-old premenopausal women. However, calcaneal BMD did not significantly change in a trial of 37 postmenopausal women who took soy isoflavone supplements (150 mg/day, but exact dose unknown). The study was conducted over a 6-month period.<sup>332</sup> Interpretation is challenging because this study was done on Taiwanese women who habitually eat soy and there was no control group. On the other hand, the calcaneus, or heel, may react differently to isoflavone treatment than the lumbar spine since it bears weight and has a higher trabecular concentration than the metatarsal bone. Chen and colleagues<sup>133</sup> conducted a double-blind, randomized clinical experiment to examine the impact of isoflavones from soybean sprout extract (40 or 80 mg/day) on postmenopausal bone loss in Chinese women (48 to 62 years) for a year, in comparison with a placebo (cornstarch). people regularly eat goods made from soy. Both univariate and multivariate analyses, with or without correction for potential bias factors, revealed that women in the high-dose group lost less bone mass in the trochanter and total proximal femur than those in the placebo or low-dose group. Supplementing with soy isoflavones only showed a beneficial effect.

In women with low-measure BMC principles. On account of the fact that the interference of soybean sprouts (especially rich in glycitein) secondhand on this have a look at differs from that of various studies (the produce are normally significantly rich in genistein), it's hard to compare the results accompanying those of added studies. But the results concerning this observation support that isoflavones concede the possibility of having a big impact at the cortical level

(close by a physical leg part or cool bone) or that the appendicular cartilage reacts in some different way than the principal (i.e., sleep-inducer) scaffolding. Kreijkamp-Kaspers and others<sup>127</sup> described the lack of impact of soy protein insulation (25.6 g/era) on cognitive function, BMD, and red body fluid lipids over three hundred and 65 days in postmenopausal women. Still, this examination covered women, the ones that happened appreciably earlier (60 to 75 years of age) than most various studies showing the effect of isoflavones. Their appendages have happened in old age, are heterogeneous in menopausal celebrities, and do not give a reason for the main confounding details. The authors established that "improvement for smoking enumerations and guideline BMD acted now not exchange effects, still, contemporary hot repute, baseline BMD (that disagreed middle from two points agencies by way of 3-5% for the complete fashionable and ~2.four% for the lumbar determination, biologically sizable alternatives), and use of antihypertensives should have existed statistically taken into concern. On account of the evidence the authors refer to, people who now had more menopausal daughters experienced better belonging (all smart and determined) after 12 months of soy, opposite to the fake pill, despite the reality that the interplay is not any more huge ( $p = 0.07$  for complete cool). This signifies that each opportunity for the purpose that menopause changed into significantly essential in recognizing the remedy impact and/or that average acting was insufficient. Their claim that "soy isoflavones (99 mg/d) are as effective as established hormone situations is wrong, and that can bring about underperformance. Those concerning details and impediments make the translation troublesome.

Gallagher and coworkers examined the effect of soy protein disconnect accompanying similar effects to isoflavones (96 or having 50 of something two mg/epoch) and without isoflavones (< four mg/epoch) on cartilage deficit and lipids in postmenopausal ladies (N =65; indicate age having 50 of something five age and seven.5 age given that end of menstrual cycle). Soy protein was reduced and provided for nine months; however, shareholders followed up without situation for a likewise six months.

Soy supplementation had no important effect on the BMD of the lumbar spine or femoral narrow connector, but BMD was drastically enhanced at the trochanter at nine months ( $p = \text{nothing}.02$ ) and 15 months ( $p < \text{nothing}.05$ ) in the isoflavone-vague soy institution, contrary to the alternative companies. but it's far harder to offer a clarification for the results. In comparison to the verdicts of the former studies, Lydeking-Olsen and others (130) referred to the fact that postmenopausal ladies (mean age 58.2, most age 75) (N = 89) inside the isoflavone-rich soy milk (76 mg/day) or transdermal progesterone (25.7 mg/era) organization acted immediately not to lose Lumbar backbone BMD, as long as a fake pill maneuver (isoflavone-awful soy milk plus no progesterone oil; -4.2%,  $p = \text{nothing}.01$ ) and the blend of isoflavone-wealthy milk and progesterone (-2.8%,  $p = 0.01$ ) associations had a broad misfortune. Everyday consumption of bifocals of soy milk accompanying 76 mg of isoflavones prevented lumbar backbone cartilage deficit, but as long as combined with accompanying progesterone lotion, lumbar backbone BMD changed into something curiously improper, still

the truth that not anymore as oodles as that of a fake pill. Equol builder's reputation evolved as expected and had a connection with a higher cartilage answer, but this act no longer acquires mathematical importance by way of the insufficient sample ending.

Taken together, the results of those human studies advocate that isoflavones may have a slight cartilage misfortune from the lumbar backbone in estrogen-poor women; alternatively, they are anticipated to drop 2–3% by annum. Such debilitating loss, especially if it continues throughout the postmenopausal period, may lead to a reduction in the risk of osteoporosis. The bone remodeling cycle ranges from 30

For 80 weeks, such short-term ( $\leq 1$  year) preliminary studies cannot answer the question of whether these bone-sparing effects would persist over a longer period. From these results, we cannot determine whether the reported bone-sparing effect is due to the treatment or is an artifact of a transient state of bone remodeling (136), although a Asian women's long-term research (131) indicates a true bone saver. To find out if soy isoflavones alter the remodeling balance and tip it in favor of bone production rather than resorption, clinical evaluation for at least two years, preferably three, is required. In the US, these studies are in progress.

#### **Biochemical Markers of Bone in Response to Soy Isoflavones**

Biochemical markers of bone function serve as markers of alterations in bone turnover, signifying a rise or fall in the rate at which bone is formed and reabsorbed. High-pressure liquid chromatography (HPLC), radioimmunoassay (RIA or IRMA), and enzyme-linked immunosorbent assay (ELISA) can all be used to measure the many indicators that can be detected in either blood or urine. Biochemical bone indicators have the benefit of being non-invasive, potentially being used more frequently than bone density scans, and having the ability to predict – albeit imperfectly – the pace of bone loss in menopausal women as well as their response to certain antiresorptive therapies{137}. Bone markers are usually assessed at the start of a study and once or more times during treatment. In the clinical setting, bone markers can be measured at baseline and several weeks after the initiation of treatment to determine whether the patient has undergone a therapeutic response. A primary limitation of bone markers is that circadian rhythms affect circulation, and biological variability is large enough to require large differences in markers to detect responses to therapy.<sup>137</sup> Another limitation is that over time, the patient's renal clearance capacity significantly affects the values of markers derived from blood and urine; sampling and measurements should be standardized; the patient's overall metabolic status at the time of sample collection must be taken into account; and some markers (i.e., non-bone-derived biomarkers) are not sensitive or specific enough to detect small changes. On the other hand, higher concentrations of markers related to both resorption and formation are linked to faster bone loss, and variations in these rates translate into clinically meaningful variations in fracture risk.<sup>138</sup> Based on available data, biochemical markers could be useful in identifying women who are more susceptible to fractures and fast bone loss.<sup>139</sup> Osteocalcin, N-terminal procollagen, and serum bone-specific alkaline phosphatase are the most

useful biomarkers for the creation of new bone. propeptide, whereas serum N- and C-telopeptides of type I collagen and cross-linking of pyridinoline and deoxypyridinoline collagen in urine are responsible for bone resorption. For information on the use of biochemical agents as indicators of bone turnover in osteoporosis, the reader is referred to the International Osteoporosis Foundation review (140).

## **METHODOLOGY**

The study underpinning the research specializes in elucidating the skeletal consequences of soy isoflavones or soy protein-containing isoflavones in human beings. The primary goal of this evaluation is to explore the capacity impact of soy intake on bone fitness, mainly bone mineral density (BMD) and bone turnover markers. The study's technique includes a thorough examination of prospective interventional research. Observational research, animal research, and in vitro cellular research were no longer taken into consideration in the scope of this evaluation. The analysis by and large hinges on records derived from potential research that employed dual-strength X-ray absorptiometry (DXA) for assessing BMD and biochemical markers of bone turnover measured in human blood or urine.

## **RESULTS**

The results of this study underline the complexity of the relationship between soy isoflavones and bone fitness. Observations recommend a probable association between soy consumption and bone fitness advantages, including the quite low price of hip fractures in Pacific Asians and the efficacy of the isoflavone derivative ipriflavone in postmenopausal osteoporosis treatment. However, those findings do not provide a definitive guide for the function of soy isoflavones in bone fitness. The potential protective effect of soy-containing isoflavones on bone health remains exciting, although speculative at this point.

## **DISCUSSIONS**

The discussion on the skeletal outcomes of soy isoflavones delves into the wider context of osteoporosis, a massive health problem with enormous implications. The silent epidemic of osteoporosis leads to a huge variety of fractures each year, contributing to extended healthcare costs and disability worldwide. Ethnic and genetic differences similarly complicate fracture susceptibility, as positive populations showcase lower hip fracture rates notwithstanding decreased bone density.

The potential role of soy isoflavones in mitigating bone loss is of interest. However, human research presents combined consequences concerning the consequences of soy consumption on bone density and fracture chance. Research indicates that isoflavone-rich soy protein consumption might also lead to useful results on spine BMD; however, the effects on femoral bone are less well known. Variations between racial and ethnic groups, in addition to variations in isoflavone consumption, may contribute to those disparities.

In light of those complexities, alternative treatments for osteoporosis are explored. Those encompass alternatives such as bisphosphonates, calcitonin, and the supplementation of calcium and vitamin D. Bisphosphonates, mainly, end up being strong inhibitors of bone resorption with proven efficacy in preventing fractures.

### **CONCLUSIONS AND RECOMMENDATIONS**

Isoflavones derived from soy proteins appear to have potential benefits for BMD, although more research is needed to confirm these initial findings. Conversely, there isn't much proof as of yet that extracted isoflavones have an impact on human bone. Nevertheless, it is impossible to say with certainty whether soy or its isoflavones promote bone growth or prevent bone resorption. We have evidence that isoflavones have estrogen-like actions in human cells because of their distinct organic structure, even if their effects may differ from those of estrogen, which has antiresorptive effects on the skeleton. Isoflavones can function as mild estrogen agonists or antagonists, depending on the tissue and species. To determine how isoflavones protect bone tissue and to confirm their effects on the skeleton, more research must be conducted. when confronted with an estrogen shortage. Evidence-based medicine should refrain from recommending isoflavones as supplements to treat or prevent osteoporosis until such data are published and a consensus is formed. They need to have advised people to eat more soy foods because of their superior nutritional profiles and other health advantages, even while we cannot advise using soy foods as an alternative to estrogen or hormone therapy. In addition to non-steroidal osteoporosis treatment, we advise perimenopausal women and early postmenopausal women to consume dietary isoflavone-containing soy products. A few studies have shown encouraging results, indicating that 60-90 mg of isoflavones per day may help maintain the bone. This preventive effect is then transferred to two to three servings of regular soy. meals. To ascertain the human dosage response and long-term safety of isoflavone supplementation, more information is nevertheless required.

## ACKNOWLEDGMENT

The accomplishment concerning this research project would not have existed without the offerings and support of many things and institutions. We are intensely. Nice to all those who performed a function for the benefit of this project.

We too kiss My mentor, Naweed Imam Syed, Prof. Department of Cell Biology at the University of Calgary, and Dr. Sadaf Ahmed, Psychophysiology Lab, University of Karachi, for their priceless recommendations and support during the whole of this research. Their observations and knowledge assisted in forming the management concerning this project. Declaration of Interest, I acknowledge that: I have no financial or additional private interest, direct or unintended, in any matter that raises or grants permission that contradicts my responsibilities as a director of my commission. Conflicts of Interest, The authors reveal that they have no conflicts of interest. Financial support and protection, No Funding was taken to assist in the development of this study.

## REFERENCES

- Agnusdei, D., Camporeale, A., Zacchei, F., Gennari, C., Baroni, M.C., Costi, D., Biondi, M., Passeri, M., Ciacca, A., Sbrenna, C., Falsetti, E., and Ventura, A., outcomes of ipriflavone on cartilage bulk and cartilage upkeep in sufferers with settled postmenopausal osteoporosis. *Curr Ther Res* fifty-two: eighty-one–ninety-two, 1992.
- Alekel, D. L., Mortillaro, E., Hussain, E. A., West, B., Ahmed, N., Peterson, C. T., Werner, R. Ok., Arjmandi, B. H., and Kukreja, S. C. way of life and natural subscribers to close to leg part cartilage now not natural bulk and elegant stem time in apparent racial groups of premenopausal moms *Osteoporos Int* 9: 327–338, 1999.
- Arjmandi, B.H., The role of phytoestrogens in the stop and state of affairs of osteoporosis in ovarian start manipulation technique imperfection *J Am Coll Nutr.* 20 (Suppl. 5): 398S–402S, 417S–420S, 2001.
- Anderson, J. J. B. Pollitzer, and W. S. Ethnic and ancestral distinctnesses: resistance to osteoporotic fractures *Advances in dietary studies*, Vol. 9, Ed. Harold H. Draper, Plenum Press, The Big Apple, 1994, lad. 8.
- Anderson, J.J.B., and Garner, S.C., Phytoestrogens and Bone *Balliere's Clin Endocrinol Metab* 12:1–15, 1998. *Balliere's Clin Endocrinol Metab* 12: 1–15, 1998.
- B. L., Khosla, S., and Melton, L. J., III. A whole version for involuntional osteoporosis: estrogen imperfection causes type I and type II osteoporosis in postmenopausal mothers and causes cartilage misfortune in developing men. *J Bone Miner Res* thirteen: 763–773, 1998.
- Breslau, N. A., Brinkley, L., Hill, OK. D., and Pak, C. Y. C., dating between animal protein-wealthy diet and type of rock establishment and calcium absorption *J Clin Endocrinol Metabol* 66: a hundred and forty–146, 1988.
- Cauley, J.A., Seeley, D.G., Ensrud, K., Ettinger, B., Black, D., and Cummings, S.R., Estrogen substitute medicinal drug and fractures in in-advance mothers: an examination of the osteoporotic break research group 1995, *Ann Intern Med* 122: 9–16.

- Chen, Y.-M., Ho, S.C., Lam, S.S.H., Ho, S.S.S., and Woo, J.L.F. Soy isoflavones have an excellent effect on bone loss in Chinese-language postmenopausal ladies with decreased bone mass: A double-blind, randomized, controlled trial. *J Clin Endocrinol Metab* 88: 4740–4747, 2003.
- Christiansen, J.S. Johansen, and B.J. Riis, N? haven A/S, Viborg, Denmark, 1987, Pie, J.-E.; Paik, H.Y. The effect of meat protein and soy protein on calcium metabolism in younger grownup Korean women *Korean J Nutr* 19: 32-40, 1986.
- Chin, OK., Evans, M.C., Cornish, J., Cundy, T., and Reid, I.R., differences in chic stem and femoral narrow connector distance in premenopausal wives of Polynesian, Asian, and European origin *Osteoporos Int* 7: 344–347, 1997
- Cooper, C., Campion, G., and Melton, L. J. III. Hip fractures in the elderly: a standard prediction. *Osteoporos Int* 2: 285–289, 1992.
- Cummings, S.R., Nevitt, M.C., Browner, W.S., Stone, OK., Fox, OK.M., Ensrud, OK.E., Cauley, J., Black, D., and Vogt, T.M., chance determinants for stylish fractures in Caucasian moms. examine the osteoporotic rupture studies organization. *N Engl J Med* 332: 767–773, 1995.
- Cummings, S. R.; Melton, L. J., III., *Osteoporosis I: Epidemiology and Results of Osteoporotic Fractures*, *Lancet* 359: 1761–1767, 2002.
- Cummings, S.R., Cauley, J.A., Palermo, L., Ross, P.D., Wasnich, R.D., Black, D., and Faulkner, K.G. Racial distinctness in fashionable pivot lengths concedes the opportunity to exhibit ethnic distinctness in stylish ruin fees. *Osteoporosis Int* 4: 226–229, 1994.
- Chen, Z., Zheng, W., Custer, L.J., Dai, Q., Shu, X.-O., Jin, F., and Franke, A.A., nutritional use of soy snacks and charm equivalence accompanying the defecation rate of isoflavonoids in adventure excretion samples with Chinese-language daughters in Shanghai. *Nutr Most Cancers* 33: 82–87, 1999.
- De Laet, C.E., Camper Hout, B.A., Burger, H., Hofman, A., and Pols, H.A., Bone mass and hazard of modern-day rupture in human beings interested in something: a pass-localized look, *Br Med J* 315: 221–225, 1997.
- Dallas, F.S., Rice, G.E., Wahlqvist, M.L., Grehan, M., Murkies, A.L., Medley, G., Ayton, R., and Strauss, B.J.G. Consequences of nutritional phytoestrogens in postmenopausal women *Climacteric* 1: 124–129, 1998.
- Delmas, P.D., Eastell, R., Garnero, P., Seibel, M.J., and Stepan, J., Committee of clinical Advisors of the worldwide Osteoporosis foundation the use of biochemical markers of bone turnover in osteoporosis. *Osteoporosis Int.* 11 (Suppl. 6): S2–17, 2000.
- Doren, M., and Samsioe, G. Prevention of postmenopausal osteoporosis accompanying estrogen substitute remedies and joined compounds: renewing dispassionate issues due to the fact 1995. *Hum Reprod Update* 6: 419–426, 2000.
- Davis, J.W., Novotny, R., Wasnich, R.D., and Ross, P.D. Ethnic, anthropometric, and conduct determinants of manual territorial differences in top cartilage bulk *Calcif Tissue Int* sixty-five: 100–a hundred and five, 1999.

- Davis, J.W., Ross, P.D., Nevitt, M.C., and Wasnich, R.D., occurrence of falls among Japanese human beings inquisitive about something in Hawaii *J Clin Epidemiol* 50: 589-594, 1997.
- Eight. Anderson, J. J. B., and Alekel, D. L. Skeletal property of phytoestrogens in humans: cartilage now, not organic bulk, and cartilage indicators *Phytoestrogens and Health* Eds. Gilani, G.S., and Anderson, J.J.B., American Oil Chemists' Society Press, Champaign, IL, 2002, pp. 341-353.
- Family members: K., Lee, E., Kushida, OK., Sartoris, D.J., Ohmura, A., Clopton, P.L., Inque, T. Bone bulk and cloth arrangement at the Pacific Rim: a corresponding middle from points Japan-Born and U.S.-innate Japanese American other halves, *J Bone Mineral Res* 8: 861-869, 1993
- Fleisch, H. Bisphosphonates in osteoporosis: an initiation *Osteoporosis Int.* 3: S3-S5, 1993.
- Fujita, T., Yoshikawa, S., Ono, OK., Inoue, T., & Orimo, H. Usefulness of TC-80 (ipriflavone) tablets in osteoporosis: A multicenter, double-blind, fake tablet-regulated examination *Igaku Noayumi* 138: 113-141, 1986.
- Gallagher, J.C., Satpathy, R., Rafferty, ok., and Haynatzka, V. The effect of soy protein isolate on bone metabolism *Menopause* 11: 290-298, 2004
- Greendale, G.A., FitzGerald, G., Huang, M.-H., Sternfeld, B., Gold, E., Seeman, T., Sherman, S., and Sowers, M.F. Nutritional soy isoflavones and cartilage now not organic mass: effects from a study of women's energy throughout the United States with its very own government *Am J Epidemiol*, 155: 746-754, 2002.
- Garnero P., Markers of bone turnover for the prediction of fracture threat. *Osteoporos Int* eleven (Suppl 6): S55-65, 2000.
- Genant, H.ok., Cooper, C., bad, G., Reid, I., Ehrlich, G., Kanis, J., Nordin, B.E.C., Barrett-Connor, E., Black, D., Bonjour, J.-P., Dawson-Hughes, B., Delmas, P.D., Dequeker, J., Ragi Eis, S., Gennari, C., Johnell, O., Johnston, C.C., Jr., Lau, E.M.C., Liberman, Lindsay, R., Martin, T.J., Martin, T.J., Martin, T.J., Masri, Mautalen, C.A., Meunier, P.J., Miller, P.D., Mithal, Morii, H., Papapoulos, S.,for Osteoporosis. *Osteoporos Int* 10: 259-264, 1999.
- Groeneveld, F.P., Bareman, F.P., Barentsen, R., Dokter, H.J., Drogendijk, A.C., and Hoes, A.W. The duration of hormonal substitute analysis is commonly practiced as an effect lookahead. *Maturitas* 29: one hundred twenty-five-131, 1998 78. Schneider D.L., Barrett-Connor E.L., and Morton D.J., Timing of postmenopausal estrogen for max cartilage, now not natural mass Rancho Bernardo study, *JAMA* 277: 543-547, 1997.
- Harkness, L.S., Fiedler, OK., Sehgal, A.R., Oravec, D., and Lerner, E. reduced bone resorption with soy isoflavone supplementation in postmenopausal ladies. *J ladies' fitness* 13: a thousand-1007, 2004.
- Heaney, R.P., The Bone-remodeling short: Implications for the interpretation of scientific studies on Bone Mass exchange *J Bone Miner Res* nine: 1515-1523, 1994.
- Heaney, R.P., Recker, R.R., and Stegman, M.R., will also be A.J. Calcium absorption in ladies: relationships to calcium consumption, estrogen popularity, and age. *J Bone Miner Res*: 469-475, 1989.



- Ho, S.C., Chan, S.G., Yi, Q., Wong, E., Leung, P. Soy intake and the protection of height bone mass in Hong Kong Chinese women. *J Bone Miner Res* sixteen: 1363-1369, 2001.
- Ho, S. C., Wong, E., Chan, S. G., Lau, J., Chan, C., and Leung, P. C. The purpose of height cartilage bulk in Chinese other halves has been antique 21-40 age. III. Bodily activity and cartilage now have organic bulk. *J Bone Miner Res* 12: 1262-1271, 1997.
- Ho, S.C., Bacon, E., Harris, T., Looker, A., and Muggi, S. Hip rupture fees in Hong Kong and the United States, 1988-1989, *Am J Public Fitness* eighty-three: 694-697, 1993.
- Hsu, C.-S., Shen, W.W., Hsueh, Y.-M., and Yeh, S.-L. Soy isoflavone supplementation in postmenopausal women: outcomes on plasma lipids, antioxidant enzyme sports, and bone density. *J Reprod Med* 46forty-six: 221-226, 2001.
- Heaney, R.P. Calcium, creamery devices, and osteoporosis *J Am Coll Nutr* 19: 83S-99S, 2000. Nieves, J.W., Komar, L., Cosman, F., and Lindsay, R. Calcium potentiates the effect of estrogen and calcitonin on cartilage bulk: evaluation and reasoning *Am J Clin Nutr* 67: 18-24, 1998.
- Kessel, B. Alternatives to estrogen in menopausal better halves, *Proc Soc Exp Biol Med* 217(1): 38-44, 1998.
- Kerstetter, J.E., O'Brien, OK., and Insogna, OK., dietary protein, and intestinal calcium absorption, *Am J Clin Nutr* 73: 990-992, 2001.
- Kimira, M., Arai, Y., Shimoi, K., and Watanabe, S., eastern consumption of flavonoids and isoflavonoids from delicacies *J Epidemiol* 8: 168-175, 1998.
- Kurzer M.S., Xu X., Nutritional phytoestrogens. *Annu Rev Nutr* 17: 353-381, 1997.
- Kuiper, G.G., Lemmen, J.G., Carlsson, B., Corton, J.C., Secure, S.H., Camper der Saag, P.T., Camper der Burg, B., and Gustafsson, J.A., the interaction of estrogenic chemical compounds and phytoestrogens accompanying estrogen receptors *Endocrinology* 139: 4252-4263, 1998.
- Kardinaal, A.F.M., Morton, M.S., Bruggemann-Rotgans, I.E.M., and Camper Beresteijn, E.C.H., Phytoestrogen expulsion and rate of cartilage deficit in postmenopausal daughters, *Eur J Clin Nutr* 52: 850-855, 1998.
- Thompson, L. U., Robb, P., Serrano, M., and Cheung, F. Mammalian lignans result from differing meals. *Nutr Cancer* 16:43-52, 1991,
- Zhang, X., Shu, X.-O., Li, H., Yang, G., Li, Q., Gao, Y.-T., and Zheng, W. Potential follower examines soy bread devouring and risk of cartilage rupture between postmenopausal daughters *Arch Intern Med* a hundred sixty-five: 1890-1895, 2005
- Komulainen, M., Kroger, H., Tuppurainen, M.T., Heikkinen, A.M., Alhava, E., Honkanen, R., Jurvelin, J., Saarikoski, S. Prevention of femoral and lumbar cartilage misfortune accompanying birth control method substitute remedy and supply of nourishment D3 in early postmenopausal other halves: A community-placed 5-period randomized trial 1999, *J Clin Endocrinol Metab* eighty-four: 546-552.

- Kanis, J.A., Melton, L.J., III, Christiansen, C., Johnston, C.C., and Khaltsev, N.: Prognosis of osteoporosis. *J Bone Miner Res* 9: 1137-1141, 1994.
- Karpf, D.B.; Shapiro, D.R.; Seeman, E.; Ensrud, K.E.; Johnston, C.C.; Adami, S.; Harris, S.T.; Santora, A.C.; Hirsch, L.J.; Oppenheimer, L.; Thompson, D. Prevention of nonvertebral fractures by way of alendronate: a meta-study *JAMA* 277(14): 1159-1164, 1997.
- Overgaard, OK., Hansen, M. A., Jensen, S. B., and Christiansen, C. Impact of following a timed nasal presidency of calcitonin on cartilage bulk and rupture costs in settled osteoporosis: A prescription-solution look at *Br Med J* 305: 556-561, 1992.
- Kung, A.W.C., Luk, adequate. D.k., Chu, L.W., and Chiu, P.k.Y. Age-related osteoporosis in Chinese language: an evaluation of the reaction of intestinal calcium absorption and calcitropic hormones to dietary calcium deprivation *Am J Clin Nutr* 68: 1291-1297, 1998.
- Kreijkamp-Kaspers, S., Kok, L., Grobbee, D.E., de Haan, E.H.F., Aleman, A., Lampe, J.W., and van der Schouten, Y.T., the effect of soy protein containing isoflavones on cognitive characteristics, bone mineral density, and plasma lipids in postmenopausal ladies *JAMA* 292: 65,74 2004.
- Lydeking-Olsen, E.; Beck-Jensen, J.-E.; Setchell, k. D.R., Holm-Jensen, T. Soy milk or progesterone for preventing bone loss: a 2 12 months randomized, placebo-controlled trial. *Eur J Nutr* 40-three: 246-257, 2004
- Lips, P., Duong, T., Oleksik, A., Black, D., Cummings, S., Cox, D., and Nickelsen, T. A all-encompassing examine of supply of nourishment D rank and parathyroid feature in postmenopausal moms accompanying osteoporosis: a well-known file from the assorted consequences of raloxifene judgment in a dispassionate trial *J Clin Endocrinol Metab* 86: 1212-1221, 2001.
- Kantorovich, V., Gacad, M.A., Seeger, L.L., and Adams, J.S. Bone, no longer organic bulk, increases accompanying supply of nourishment D satiation in inmates with accompanying supply of nourishment D lack and fundamental hyperparathyroidism. *J Clin Endocrinol Metab* 85: 3541-3543, 2000.
- Adams, J.S., Kantorovich, V., Wu, C., Javanbakht, M., and Hollis, B.W. Decision of the supply of nourishment D lack in osteopenic victims consequences in the speedy development of cartilage, no longer organic mass. *J Clin Endocrinol Metab* 84: 2729-2730, 1999.
- 97 Bryant, H. U.; Dere, W. H. Selective estrogen receptor modulators: an alternative to delivery control techniques and an alternative therapy *Proc Soc Exp Biol Med* 217(1): 45-52, 1998
- Havsteen B. Flavonoids, a class of regular compounds accompanying severe pharmacological effectiveness *Biochem Pharmacol* 32: 1141-1148, 1983.
- 99.
- Agnusdei, D., Zacchei, F., Bigazzi, S., Cepollaro, C., Nardi, P., Montagnani, M., Gennari, C. Metabolic and dispassionate outcomes of ipriflavone in postmenopausal osteoporosis drugs *Exp Clin Res* 15: 97-104, 1989.
- 100 Yamazaki I, Shino A, Shimizu Y., Tsukuda R., Shirakawa Y., and Kinoshita M. Impact of ipriflavone on glucocorticoid-inferred

- osteoporosis in rats *Sci*. 38: 951-958, 1986.
- Yamazaki, I., Shino, A., and Tsukuda, R. Effect of ipriflavone on ovariectomy-caused osteoporosis in rats *J Bone Min Metab* 3: 205-210, 1986.
- Dei D., Gennari C., and Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone *Osteoporos Int* five(6): 462-466, 1995.
- Alexandersen, P., Toussaint, A., Christiansen, C., Devogelaer, J.-P., Roux, C., Fechtenbaum, J., Gennari, C., and Reginster, J.Y., for the Ipriflavone Multicenter European Fracture, examine Ipriflavone inside the remedy of postmenopausal osteoporosis. *JAMA* 285: 1482-1488,
- Looker, A.C., Orwoll, E.S., Johnston, C.C., Jr., Lindsay, R.L., Wahner, H.W., Dunn, W.L., Calvo, M.S., Harris, T.B., and Heyse, S.P., the incidence of reduced femoral cartilage mass in earlier American folks from NHANES III. *J Bone Miner Res* 12: 1761-1768, 1997.
- Lau, E. M. C., Suriwongpaisal, P., Lee, J. K., Das De, S., Festin, M. R., noticed, S. M., Khir, A., Torralba, T., Sham, A., and Sambrook, P. Risk determinants for elegant spoilage in Asian people of community: The Asian Osteoporosis Study, *J Bone Miner Res* 16: 572-580, 2001.
- Lau, E.M.C., Osteoporosis in Asians: The characteristic of Calcium and exceptional nutrients *Mod Med* 7: 45-50, 1994.
- Liberman, S. Are the dissimilarities betwixt estradiol and introduced estrogens always happening or artificial, truly bearing on syntax? *J Clin Endocrinol Metab* 81:850, 1996.
- Markiewicz, L.; Garey, J.; Adlercreutz, H.; Gurrpide, E. In vitro biochemical assays of nonsteroidal phytoestrogens. *J Steroid Biochem Mol Biol* 45: 399-405, 1993.
- Maskarinec, G., Singh, S., Meng, L., and Franke, A. A., dietary soy consumption and urinary isoflavone expulsion between daughters in a multiethnic human being: most cancers *Epidemiol Biomark Prev* 7: 613-619, 1998.
- Manolagas, S. C., and Jilka, R. L. Mechanisms of agony: cartilage essence, cytokines, and cartilage protection: rising visions into the pathophysiology of osteoporosis 1995, *N Engl J Med* 332:305-311. 71.
- Scharbo-DeHaan, M. Hormone replacement analysis *Nurs: Pract.* 21 (12 Pt. 2): 1-13, 1996.
- Beresford S.A.A., Weiss N.S., McKnight B. Hazard of endometrial malignancy having to do with the usage of estrogen-linked accompanying recurrent progestagen medicine in postmenopausal women. *Lancet* 349: 458-461, 1997.
- McNagny, S.E., Prescription of Start Manipulating Techniques as Alternative Cures for Menopausal Syndromes *Ann Intern Med* 131: 605-616, 1999.
- Eastell, R. Postmenopausal osteoporosis state of affairs, *N Engl J Med* 338: 736-746, 1998.
- Messina, M., Gugger, E. T., and Alekel, D. L. Soy protein, soybean isoflavones, and cartilage health: an evaluation of animal and human files *Soy protein, soybean isoflavones, and cartilage power: an evaluation of the animal and human file within the guide to Nutraceuticals and purposeful ingredients,*

- R.E.C. Wildman (Ed.), CRC Press, Boca Raton, FL, 2001, pp. 77-98,
- Melton, L.J., III; Chrischilles, E.A.; Cooper, C.; Lane, A.W.; Riggs, B.L. attitude: how many wives do you have with osteoporosis? *J Bone Miner Res* 7: 1005-1010, 1992.
- Melton, L. J., III; Therneau, T. M.; Larson, D. R., Long-time period flows in elegant ruin predominance: the influence of contemporary rupture occurrence and endurance. *Osteoporos Int.* 8: 68-74, 1998.
- Melton, L.J., III; Riggs, B.L., *Epidemiology of Person-Related Fractures: Osteoporotic Syndrome*, Ed. Avioli, A.V., New York, Grune and Stratton, 1983, pp. 45-72.\
- Melton, L.J., III. Who has osteoporosis? The conflict between dispassionate and community fitness outlooks *J Bone Miner Res.* 15: 2309-2314, 2000.
- Melton, L.J., III., On what number of other halves do you have osteoporosis? *J Bone Miner Res.*, 10: a hundred seventy-five-177, 1995.
- Morgan, S.L., Calcium, and source of nutrition D tiers in osteoporosis *Rheum Dis Clin N Am* 27: 101-130, 2001. meals and Nutrition Board, Institute of Drugs: Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, vitamin D, and Fluoride Washington, D.C.: Countrywide Academy Press, 1997.
- Nine. Anthony, M.S., Anderson, J.J.B., and Alekel, D.L., Affiliation between soy and/or isoflavones and cartilage: proof from epidemiological studies. *Phytoestrogens and fitness*, Eds., Gilani, G.S., and Anderson, J.J.B., American Oil Chemists' Society Press, Champaign, IL, 2002, pp. 331-340.
- Nakamura, T., Turner, C.H., Yoshikawa, T., Slemenda, C.W., Peacock, M., Burr, D.B., Mizuno, Y., Orimo, H., Ouchi, Y., and Johnston, C.C., Jr. Do alternatives in current mathematics analyze the dissimilarities in modern damage hazards between Japanese and White Americans? *J Bone Miner Res* 9: 1071-1076, 1994.
- Parker, M., Anand, J. okay., Myles, J. W., and Lodwick, R. Proximal femoral fractures: predominance of detached ethnic agencies *Eur J Epidemiol* 8: 730-732, 1992.
- Prentice, A.; Parsons, T.J.; Cole, T.J. The unfussy use of cartilage no longer organic bulk in absorptiometry concedes the opportunity to bring about period-accompanying artifacts within the labeling of cartilage no longer organic cause. *Am J Clin Nutr* 60: 837-842, 1994.
- Potter, S.M., Baum, J.A., Teng, H., Stillman, R.J., Shay, N.F., and Erdman, J.W., Jr., consequences of soy protein and isoflavones on ancestry lipids and cartilage bulk in postmenopausal girls, *Am J Clin Nutr* 68: 1375S-1379S, 1998.
- Pun, k.good enough., Chan, L.W.L., Chung, V., and Wong, F.H.W. Calcium and specific nutritional components in Hong Kong Chinese language concerning age and osteoporosis *J Appl Nutr* 40-3: 12-17, 1990.
- Pines, A., Katchman, H., Villa, Y., Mijatovic, V., Dotan, I., Levo, Y., Ayalon, D. The impact of numerous hormonal arrangements and calcium supplementation on bone mass in early menopause. Is there a predictive cost for the preliminary bone density and frame weight? *J Intern Med* 246:

357-61 1999

- Ross, P.D., Norimatsu, H., Davis, J.W., Yano, K., Wasnich, R.D., Fujiwara, S., Hosoda, Y., and Melton, J., III. assessment of smart rupture occurrence between native eastern, Japanese American, and American Caucasian societies, *Am J Epidemiol* 133: 801-809, 1991.
- Rogmark, C., Sernbo, I., Johnell, O., and Nilsson, J.-., the incidence of recent fractures Malmö, Sweden, 1992-1995. *Acta Orthopaed Scand* 70: 19-22, 1999.
- Ross, P.D., He, Y.-F., Yates, A.J., Coupland, C., Ravn, P., McClung, M., Thompson, D., and Wasnich, R.D. The frame amount accounts for most of the differences in cartilage mass between Asian and Caucasian ladies. *Calcif Tissue Int* 59: 339-343, 1996.
- Ross, P.D., Fujiwara, S., Huang, C., Davis, J.W., Epstein, R.S., Wasnich, R.D., Kodama, okay., and Melton, J., III. Vertebral rupture predominance in moms in Hiroshima outstanding to Caucasians or Japanese daughters inside the U.S. *Int J Epidemiol* 24: 1171-1177, 1995.
- Roughead, Z. good enough., Hunt, J.R., Johnson, L. good enough., Badger, T.M., and Lykken, G.I., controlled substitution of soy protein for meat protein: outcomes on calcium retention, bone, and cardiovascular health indices in postmenopausal ladies. *J Clin Endocrinol Metab* 90: 181-189, 2005.
- Ross, P.D., Predicting bone loss and fracture dangers with biochemical markers: an overview *J Clin Density Geometry* 2: 285-294, 1999.
- Scheiber, M.D.; Rebar, R.W. Isoflavones and postmenopausal cartilage well-being: a possible alternative to estrogen treatment? *Menopause* 6: 233-241, 1999.
- Setchell, OK.D., and Cassidy, A., dietary isoflavones: organic assets and pertinence to human well-being, *J Nutr* 129: 758S-767S, 1999.
- Somekawa, Y., Chiguchi, M., Ishibashi, T., and Aso, T. Soy intake had references to menopausal manifestations, antitoxin lipids, and cartilage, not natural bulk, in postmenopausal Japanese mothers. *Obstet Gynecol Ninety-Seven*: 109-a hundred and fifteen, 2001.
- Setchell, ok. D.R. Non-steroidal estrogen of abstinence from food inception: workable responsibility in well-being and agony, absorption, and corporal property, *Proc Nutr Soc NZ* 20: 1-21, 1995.
- Shutt, D. A.; Cox, R. I. Steroid and phytoestrogen binding to the chief uterine receptors is artificial. Steroid and phytoestrogen binding in a mass of water debris in air uterine receptors is artificial. *Endo Chronicle fifty-two*: 299-310, 1972
- Sebastian, A. Low versus excessive meat diets: effects on calcium metabolism *J Nutr* 133: 3237-3238, 2003.
- Souberbielle, J.C., Cormier, C., and Kindermans, C. Bone markers in clinical exercise *Curr Opin Rheu metal* 11: 312-319, 1999.
- Silverman, S.L., and Madison, R.E., decreased incidence of present-day fractures in Hispanics, Asians, and Blacks: California Clinic Discharge Dossier, *Am J Public Health* 78: 1482-1483, 1988.

- Tsai, okay.S. Osteoporotic wreck price, cartilage no longer having natural bulk, and cartilage absorption in Taiwan, *J Formos Med Assoc.*, ninety-six: 802–805, 1997.
- Tune, T.T., Hendrich, S., and Murphy, P.A. Estrogenic motion of glycitein, a soy isoflavone *J Agric Meals Chem* 47: 1607–1610, 1999. Tucci, J.R., Osteoporosis Renovation *Med Fitness R I* 81: 169–73, 1998.
- Tsai, okay., Twu, S., Chieng, P., Yang, R., and Lee, T., the incidence of vertebral fractures in Chinese people in Taiwanese towns *Calcif Tissue Int* 59: 249–253, 1996.
- Tsai, okay., Huang, K., Chieng, P., and Su, C. Bone is not the natural bulk of ordinary Chinese daughters in Taiwan. *Calcif Tissue Int* 48: 161–166, 1991.
- Tsuchida is okay; Mizushima is okay; Toba is okay; and Soda is okay. nutritional soybean intake and cartilage, not organic mass, among 995 middle-vintage daughters in Yokohama. *J Epidemiol* 9: 14–19, 1999.
- Thamsborg G.: effect of a nasal mixture of pink and yellow calcitonin on calcium and cartilage absorption *Dan Med Bull* 46: 118–126, 1999.
- Silverman, S.L.: Calcitonin *Rheum Dis Clin N Am* 27: 187–196, 2001.
- Ilich, J.Z.; Kerstetter, J.E. Nutrients in cartilage strength are known as A and similarly calcium. *J Am Coll Nutr* 19: 715–737, 2000.
- North American Menopause Society. The act of calcium in fairy- and postmenopausal girls: the unity belief of the North American Menopause Society *Menopause* 8: 84–95, 2001.
- U.S. Preventive offerings assignment pressure Postmenopausal delivery manipulation techniques substitute therapy for the fundamental forestall of incessant environments: suggestions and movement. *Ann Intern Med* 137: 834–839, 2002.
- Watkins, T.R., Pandya, okay., and Mickelsen, O. Urinary acid and calcium excretion: impact of soy versus meat in human diets In nutritional Bioavailability of Calcium, Ed. Kies, C. American Chemical Society, Washington, D.C., 1985
- Vidal, O., Kindblom, L. G., and Ohlsson, C. Expression and localization of estrogen receptors in rodent and human cartilages *J Bone Mineral Res* 14: 923–929, 1999.
- Watts, N.B. Treatment of osteoporosis accompanying bisphosphonates *Rheum Dis Clin N Am* 27: 197–214, 2001.
- Adachi, J.D., Bensen, W.G., Brown, J., Hanley, D., Hodsmann, A., Josse, R., Kendler, D.L., Lentle, B., Olszynski, W., St. Marie, L.-G., Tenenhouse, A., & Chines, A.A. Interdenominational evaluation for fear of corticosteroid-inferred osteoporosis *N Engl J Med* 337: 382–387, 1997.
- Liberman, U.A., Weiss, S.R., Broll, J., Minne, H.W., Quan, H., Bell, N.H., Rodriguez-Portales, J., Downs, R.W., Jr., Dequeker, J., Favus, M. Effect of spoken alendronate on cartilage, no longer organic bulk, and the prevalence of fractures in postmenopausal osteoporosis Alendronate segment III Osteoporosis treatment look at organization *N Engl J Med* 333(22): 1437–1443, 1995.

- Weaver, C.M. Calcium necessities: the need to understand racial versions  
Editorial. *Am J Clin Nutr* 68: 1153–1154, 1998.
- Writing group for ladies' fitness Initiative Investigators dangers and blessings of  
estrogen and progesterone in healthy postmenopausal girls *JAMA* 288:  
321-333, 2002.
- Wright, C.D.P., Garrahan, N.J., Stanton, M., Gazet, J.-C., Mansell, R.E., and  
Compston, J.E. impact of lengthy-term tamoxifen therapy on cancellous  
bone reworking and shape in women with breast cancer *J Bone Miner Res*  
9: 153–159, 1994. a hundred and five. Love, R.R., Mazess, R.B., Barden,  
H.S., Epstein, S., Newcomb, P.A., Jordan, V.C., Carbone, P.P., and De  
Mets, D.L. outcomes of tamoxifen on bone mineral density in  
postmenopausal ladies with breast cancer *N Engl J Med* 326: 852–856,  
1992. 106. Fornander, T., Rutquist, L.E., Cedermark, B., Glas, U., Mattsson,  
A., Silfversward, C., Skoog, L., Somell, A., Theve, T., Wilking, N.,  
Askergren, J., Hjalmar, M.-L. Adjuvant tamoxifen for early breast cancer:  
incidence of recent primary cancers *Lancet* 1: 117–120, 1989.
- Delmas, P.D., Bjarnason, N.H., Mitlak, B.H., Ravoux, A.-C., Shah, A.S.,  
Huster, W.J., Draper, M., Christiansen, C. results of raloxifene on bone  
mineral density, serum ldl cholesterol concentration, and uterine  
endometrium in postmenopausal girls *N Engl J Med* 337: 1641–1647, 1997.
- Heaney, R. P.; Draper, M. W. Raloxifene and estrogen: comparative bone  
remodeling kinetics *J Clin Endocrinol Metab* 82: 3425–3429, 1997.
- Walsh, B.W., Kuller, L.H., Wild, R.A., Paul, S., Farmer, M., Lawrence, J.B.,  
Shah, A.S., and Anderson, P.W. results of raloxifene on serum lipid and  
coagulation aspect tiers in healthy postmenopausal girls *JAMA* 279(18):  
1445–1451, 1998. 110.
- Gordon, S., Walsh, B.W., Ciaccia, A.V., Siddhanti, S., Rosen, A.S., and  
Pouffe, L. Transition from estrogen-progestin to raloxifene in  
postmenopausal girls: impact on vasomotor signs and symptoms *Obstet  
Gynecol* 103: 267–273, 2004.
- St. Germain, A., Peterson, C.T., Robinson, J., and Alekel, D.L. Isoflavone-  
rich or isoflavone-poor soy protein did no longer reduce menopausal  
signs during the 24 weeks of treatment. *Menopause*, 8(1): 17–26, 2001
- Arjmandi, B.H., Alekel, L., Hollis, B.W., Amin, D., Stacewicz-Sapuntzakis,  
M., Guo, P., and Kukreja, S.C. nutritional soybean protein prevents bone  
loss in an ovariectomized rat version of osteoporosis. *J Nutr* 126: 161–167,  
1996. Arjmandi,  
B.H., Salih, M.A., Herbert, D.C., Sims, S.H., Kalu, D.N. evidence of  
estrogen receptor-connected calcium delivery within the gut *Bone Miner*  
21: 63–74; 1993.
- Spence, L.A., Lipscomb, E.R., Cadogan, J., Martin, B., Wastney, M.E.,  
Peacock, M., and Weaver, C.M. impact of soy isoflavones on calcium  
metabolism in postmenopausal women: A randomized crossover look at  
*Am J Clin Nutr* 81: 916–922, 2005.
- Pennington, J.A.T. *Bowes, and the Church's food Values of quantities  
commonly Used*, 17th ed. Harper and Row (1998)

- Anderson, J., Thomsen, k., and Christiansen, C. High-protein meals, insular hormones, and urinary calcium excretion in human topics In lawsuits of the worldwide Symposium on Osteoporosis, Eds., C.
- Xu, L., Lu, A., Zhao, X., Chen, X., and Cummings, S. R. Very reduced prices of new smash have taken place in Beijing, according to humans as political entities in the Republic of China and the Beijing Osteoporosis Task. *Am J Epidemiol* one hundred forty-four: 901-907, 1996.